Instil Bio, Inc.
TILNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · NY · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 | $138,000 |
| Operating income | −$78.6M | −$73.5M | −$159.2M | −$226.5M | −$155.6M | −$33.6M |
| Net income | −$71.4M | −$74.1M | −$156.1M | −$223.2M | −$156.8M | −$37.7M |
| Total assets | $203.5M | $263.6M | $325.6M | $482.1M | $610.0M | $319.0M |
| Total liabilities | $89.7M | $94.1M | $99.8M | $118.5M | $54.8M | $26.6M |
| Equity | $113.9M | $169.4M | $225.8M | $363.6M | $555.2M | −$39.6M |
| EPS (diluted) | $-10.70 | $-11.39 | $-24.00 | $-34.46 | $-1.48 | $-2.36 |
| Shares out. | 6.5M | 6.5M | 130.1M | 129.1M | 129.0M | 20.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −62.7%
- Return on assets
- −35.1%
- Return on capital (ROCE)
- −39.6%
- Liabilities / assets
- 44.1%
- Debt / equity
- 0.79×
- Book value / share
- $17.45
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -6.88distress
- Accruals / assets
- −17.1%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Bml Investment Partners, L.P.Passive (13G)Feb 9, 2026
- Vivo Capital Ix, LlcPassive (13G)Aug 12, 2025
- Boxer Capital Management, LlcPassive (13G)May 15, 2025
- Perceptive Advisors LlcPassive (13G)May 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 231,366 | 7.7 | -11.2% |
| Apr 30, 2026 | 260,419 | 17.9 | -20.7% |
| Apr 15, 2026 | 328,526 | 9.3 | -20.8% |
| Mar 31, 2026 | 414,920 | 17.2 | +4.0% |
| Mar 13, 2026 | 398,818 | 13.9 | -4.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 15, 2026
- Changed auditorApr 3, 2026
- Results of operationsMar 27, 2026
- Terminated a material agreementJan 6, 2026
- Results of operationsNov 13, 2025
- Results of operationsAug 13, 2025
- Other material eventJul 31, 2025
- Shareholder voteMay 28, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.